The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
gotbesirius, much appreciated.
From the below I think we can draw our own conclusions on valuation at year end but circa £200m market cap plus whatever we get for Imutex looks easily achievable imho
Then on top of this there's Imutex..... Probably the main reason I invested....
Imutex is an unlisted company that orph own a 49% share in that have developed a range of vaccines and treatments, some of which can be targeted at covid but one of which is one of only two universal flu vaccines that's stage 3 ready (final trial before production) they also have a mosquito v vaccine which Is at stage 2 which has been called the Holy grail of vaccines after phase 1 testing. The valuation of this company is anywhere from £100-£500m with a similar company selling recently for higher end of that range. CEO has promised to sell or list Imutex in US and all proceeds will be returned as a dividend or a free ride with one orph share for one Imutex share in a nasdaq listed company. In short this could be absolutely massive on Imutex alone. This will be monitised.... Only question is for how much? For example, even if they sell Imutex for £100m we get a £49m divided equivalent to around 7p per share....
Highlights are raised £12m at 11p last month giving cash position of £16m. Current company valuation circa £80m. Own Hvivo and Venn which complement each other as pharmaceutical service companies. Hvivo is the absolute gem, Neil Woodford invested £110m into developing facilities, labs and took the valuation to £200m in 2016...but when he was forced to liquidate his fund the share price collapsed and orph picked them up for £13m in Jan. The beauty with Hvivo is they are world leader in testing vaccines and anti virals..... (could a company be more on trend right now). They are developing the world's first challenge study model for Covid 19 which will allow vaccines to be tested on humans in lab environment and fast track successful vaccines into development. They also offer lab services and anti body testing for covid and are creating a broader antigen testing package for Covid and Flu. In short they have around £160m pipeline of work. Most pharma companies once profitable trade at 3x revenue.... Orph will be profitable this quarter after six months of huge cost cutting. I'd guide this years revenue to be £60-£80m.....thereafter much higher as more and more vaccines come into the lab for human testing.
Is anyone able to summarize the company and potential share price at the year end?
seems to have a lot going on and difficult to know what the value drivers for the year